Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells

• 作者： Bing Liang ¹ Junhui Chen ² Tao Li ³ Haiying Wu ⁴ Wenjie Yang ¹ Yanjiao Li ⁵ Jianchun Li ¹ Congtao Yu ² Fangang Nie ¹ Zhaoxia Ma ⁵ Mingxi Yang ¹ Panrong Nie ⁶ Yanfeng Gao ^2,7 Chuanyun Qian ⁴ Min Hu ^2,5,8
• 作者单位：
  1.  Department of Critical Care Medicine, Baoshan People s Hospital, Baoshan 678000, China
  2.  Intervention and Cell Therapy Center, Peking University Shenzhen Hosptial, Shenzhen 518035, China
  3.  Yunnan Yasheng Medical Technology Co., Ltd., Kunming 650021, China
  4.  Emergency Department of the First Affiliated Hospital of Kunming Medical University, EICU/MICU, Kunming 650032, China
  5.  Yunnan Key Laboratory for Basic Research on Bone and Joint Diseases & Yunnan Stem Cell Translational Research Center, Kunming University, Kunming 650214, China
  6.  Department of Neonatology, Baoshan People s Hospital, Baoshan, 678000, China
  7.  School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 517108, China
  8.  Yunnan Jici Institute for Regenerative Medicine co., Ltd., Kunming 650106, China
• 通讯作者： Yanfeng Gao  Email:yfgao@hotmail.com Chuanyun Qian  Email:qianchuanyun@126.com Min Hu  Email:huminynkm@163.com
• 提交时间：2020-02-27

摘要: BackgroundThe COVID-19 cases increased very fast in the last two months. The mortality among critically ill patients, especially the elder ones, was relatively high. Considering that most of the dead patients were caused by severe inflammation response, it is very urgent to develop effective therapeutic agents and strategies for these patients. The human umbilical cord mesenchymal stem cells (hUCMSCs) have shown very good capability to modulate immune response and repair the injured tissue with good safety. Case PresentationHere, we reported the treatment process and clinical outcome of a 65-year-old female critically ill COVID-19 patient infected with 2019-nCoV (now called SARS-CoV-2). The significant clinical outcome and well tolerance was observed by the adoptive transfer of allogenic hUCMSCs.ConclusionsOur results suggested that the adoptive transfer therapy of hUCMSCs might be an ideal choice to be used or combined with other immune modulating agents to treat the critically ill COVID-19 patients.

Abstract: 该论文正式发表的链接如下：https://journals.lww.com/md-journal/Fulltext/2020/07310/Clinical_remission_of_a_critically_ill_COVID_19.79.aspx

• 来自： 高艳锋
• 分类： 医学、药学 >> 临床医学
• 引用： ChinaXiv:202002.00084 (或此版本 ChinaXiv:202002.00084V1)
  doi:10.12074/202002.00084
  CSTR:32003.36.ChinaXiv.202002.00084.V1
• 推荐引用方式： Bing Liang,Junhui Chen,Tao Li,Haiying Wu,Wenjie Yang,Yanjiao Li,Jianchun Li,Congtao Yu,Fangang Nie,Zhaoxia Ma,Mingxi Yang,Panrong Nie,Yanfeng Gao,Chuanyun Qian,Min Hu.(2020).Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells.中国科学院科技论文预发布平台.[ChinaXiv:202002.00084] (点此复制)